Search - tctmd.com

Displaying 41 - 50 of 50

Sort: Relevancy | Date

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Brij Maini

October 15, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

June 18, 2015

News Daily News

Pharmacists May Help Ameliorate Substantial Variation in Dabigatran Adherence

Todd Neale

April 17, 2015

Presentation VEINS 2014

How to Interpret Hypercoagulable Laboratory Results while your patient is on one of the NOACs

Presenter: John R. Bartholomew

October 10, 2014

Presentation VEINS 2014

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

Presenter: James B. Froehlich

October 10, 2014

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Advertisement

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

Pharmacists May Help Ameliorate Substantial Variation in Dabigatran Adherence

How to Interpret Hypercoagulable Laboratory Results while your patient is on one of the NOACs

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content